Advertisement

Annals of Hematology

, Volume 95, Issue 6, pp 1023–1025 | Cite as

Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia

  • Sarah Lindner
  • Tobias Berg
  • Julia Riemann
  • Salem Ajib
  • Zuzana Jedlickova
  • Saskia Gueller
  • Fabian Lang
  • Hans Martin
  • Hubert Serve
  • Andrea Bacigalupo
  • Gesine BugEmail author
Letter to the Editor

Dear Editor,

Patients with high-risk acute myeloid leukemia (AML) who lack an at least 9/10 HLA-allele matched donor are considered candidates for an HLA-haploidentical family donor bone marrow transplantation (BMT) with post-transplantation cyclophosphamide (PT-Cy) as graft-versus-host (GvHD) prophylaxis [1]. PT-Cy is known to preferentially eliminate alloreactive cells, preserve regulatory T cells, and has proven to be safe and effective in preventing acute and chronic GvHD [2]. Despite encouraging results in the setting of haploidentical [3, 4, 5] and also matched donor transplants [6], the feasibility of using PT-Cy after a mismatched unrelated donor (MMUD, i.e., discrepancies in 2/10 HLA loci) BMT [7] has to date not been reported.

Between June 2012 and June 2015, 11 consecutive patients with high-risk AML were grafted with unmanipulated bone marrow from a haploidentical family donor (n = 6) or—if such a donor was unavailable—a MMUD (n = 5) using cyclophosphamide (50 mg/kg on...

Keywords

Acute Myeloid Leukemia Hematopoietic Stem Cell Transplantation Fludarabine Acute GvHD Chronic GvHD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We are grateful to the Alfred und Angelika Gutermuth-Stiftung and the KGF Stiftung for support of our transplant program.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, Solomon SR (2013) T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 31(10):1310–1316. doi: 10.1200/JCO.2012.44.3523 CrossRefPubMedGoogle Scholar
  2. 2.
    Luznik L, Fuchs EJ (2010) High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 47(1–3):65–77. doi: 10.1007/s12026-009-8139-0 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Varaldo R, Ghiso A, Gobbi M, Carella AM, Signori A, Galaverna F, Bacigalupo A (2014) Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 20(10):1573–1579. doi: 10.1016/j.bbmt.2014.05.029 CrossRefPubMedGoogle Scholar
  4. 4.
    McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolanos-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL (2015) Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 125(19):3024–3031. doi: 10.1182/blood-2015-01-623991 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O’Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringden OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen M (2015) Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126(8):1033–1040. doi: 10.1182/blood-2015-04-639831 CrossRefPubMedGoogle Scholar
  6. 6.
    Kanakry CG, Tsai HL, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L (2014) Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124(25):3817–3827. doi: 10.1182/blood-2014-07-587477 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Vina M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C (2014) Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood 124(16):2596–2606. doi: 10.1182/blood-2014-05-576041 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A (2013) Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19(1):117–122. doi: 10.1016/j.bbmt.2012.08.014 CrossRefPubMedGoogle Scholar
  9. 9.
    Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SO (2015) Optimal threshold and time of absolute lymphocyte count assessment for outcome prediction after bone marrow transplantation. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2015.10.020 PubMedGoogle Scholar
  10. 10.
    Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S, Gorin NC, Koc Y, Wu D, Beelen D, Tischer J, Ehninger G, Arcese W, Nagler A, Mohty M (2015) A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia 29(5):1069–1075. doi: 10.1038/leu.2014.336 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Sarah Lindner
    • 1
  • Tobias Berg
    • 1
  • Julia Riemann
    • 1
  • Salem Ajib
    • 1
  • Zuzana Jedlickova
    • 1
  • Saskia Gueller
    • 1
  • Fabian Lang
    • 1
  • Hans Martin
    • 1
  • Hubert Serve
    • 1
  • Andrea Bacigalupo
    • 2
  • Gesine Bug
    • 1
    Email author
  1. 1.Department of Medicine II, Hematology and Oncology, University Hospital FrankfurtGoethe UniversityFrankfurt am MainGermany
  2. 2.Universita’ Cattolica del Sacro CuoreFondazione Policlinico Universitario GemelliRomeItaly

Personalised recommendations